Prevalence of clOpidogrel 'resIstaNce' in a selected population of patients undergoing elective percutaneous coronary intervention at a tertiary cardiovascular centre in Trinidad: the POINT pilot study

Naveen Anand Seecheran, Aarti Maharaj, Brent Boodhai, Rajeev Seecheran, Valmiki Seecheran, Sangeeta Persad, Koomatie Ramsaroop, Sherry Sandy, Stanley Giddings, Sateesh Sakhamuri, Ronan Ali, Shastri Motilal, Surujpal Teelucksingh, Antonio Tello-Montoliu, Naveen Anand Seecheran, Aarti Maharaj, Brent Boodhai, Rajeev Seecheran, Valmiki Seecheran, Sangeeta Persad, Koomatie Ramsaroop, Sherry Sandy, Stanley Giddings, Sateesh Sakhamuri, Ronan Ali, Shastri Motilal, Surujpal Teelucksingh, Antonio Tello-Montoliu

Abstract

Objectives: This novel, pilot study aimed to assess the estimated prevalence of high on-treatment platelet reactivity (HPR) in Trinidad and Tobago.

Methods: Patients (n=40) who were awaiting elective percutaneous coronary intervention on maintenance dual antiplatelet therapy (DAPT) with aspirin 81 mg daily and clopidogrel 75 mg or loaded at least 48 hours prior were recruited. Platelet reactivity with the VerifyNow P2Y12 assay (Accriva Diagnostics, San Diego, California, USA) was assessed prior to cardiac catheterisation.

Results: 60.7% (17/28) of the South Asian (Indo-Trinidadians) patients had HPR, whereas 14.3% (1/7) of Africans and 40% (2/5) of mixed ethnicity had HPR. There was a significant association between HPR (P2Y12 reaction units >208) and ethnicity with South Asians (Indo-Trinidadians) (OR 5.4; 95% CI 1.18 to 24.66, p=0.029).

Conclusions: This pilot study serves to introduce the preliminary observation that the estimated prevalence of HPR is considerably higher within the heterogeneous population in Trinidad at 50% as compared with predominantly Caucasian studies. Furthermore, the HPR is significantly higher in South Asians (Indo-Trinidadians) (>60% of patients) which has severe clinical repercussions considering the cardiovascular disease pandemic. Clopidogrel may not be a satisfactory or optimal antiplatelet agent in this subgroup, and therefore, another more potent antiplatelet such as ticagrelor should be used instead. Further large-scale studies are imperative to confirm these findings. (Funded by the University of the West Indies, St. Augustine; POINT ClinicalTrials.gov number, NCT03667066.).

Conflict of interest statement

Competing interests: None declared.

References

    1. Tantry US, Bonello L, Aradi D, et al. . Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261–73. 10.1016/j.jacc.2013.07.101
    1. Mega JL, Close SL, Wiviott SD, et al. . Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354–62. 10.1056/NEJMoa0809171
    1. Matetzky S, Shenkman B, Guetta V, et al. . Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109 10.1161/01.CIR.0000130846.46168.03
    1. Ahn SG, Lee SH, Yoon JH, et al. . Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv 2012;5:259–67. 10.1016/j.jcin.2011.12.009
    1. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 2009;32:525–7. 10.2337/dc08-1865
    1. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005;45:1157–64. 10.1016/j.jacc.2005.01.034
    1. Gurbel PA, Bliden KP, Hiatt BL, et al. . Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107:2908–13. 10.1161/01.CIR.0000072771.11429.83
    1. Müller I, Besta F, Schulz C, et al. . Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89:783–7. 10.1055/s-0037-1613462
    1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. . Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101–8. 10.1016/j.thromres.2004.07.007
    1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. . Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430–5. 10.2337/diabetes.54.8.2430
    1. Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007;120:311–21. 10.1016/j.thromres.2006.08.012
    1. Agency CI. The CIA World Factbook 2016. Skyhorse Publishing, Inc, 2015: 976.
    1. Seecheran N, Baldeo S, Balbosa K, et al. . Epidemiologic insight into Trinidad’s awareness and prevention of heart disease. The EPITAPH study - a trinidadian cardiovascular health literacy survey. Int J Community Med Public Health 2017;4 10.18203/2394-6040.ijcmph20171305
    1. CSO Publications & Documents. Available: [Accessed 15 Feb 2018].
    1. PAHO Health in the Americas PAHO Health in the Americas Website. Available: [Accessed 30 Jan 2018].
    1. Beckles GLA, Kirkwood BR, Carson DC, et al. . High total and cardiovascular disease mortality in adults of Indian descent in Trinidad, unexplained by major coronary risk factors. The Lancet 1986;327:1298–301. 10.1016/S0140-6736(86)91221-3
    1. Miller GJ, Cooper JA, Beckles GL. Cardiorespiratory fitness, all-cause mortality, and risk of cardiovascular disease in Trinidadian men--the St James survey. Int J Epidemiol 2005;34:1387–94. 10.1093/ije/dyi193
    1. Christie B. Doctors revise Declaration of Helsinki. BMJ 2000;321:913 10.1136/bmj.321.7266.913
    1. Wiley Encyclopedia of Clinical Trials , 2008. International Conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Available: 10.1002/9780471462422.eoct457
    1. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. . A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J 2011;32:838–46. 10.1093/eurheartj/ehq494
    1. Angiolillo DJ, Saucedo JF, Deraad R, et al. . Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the swap (switching anti platelet) study. J Am Coll Cardiol 2010;56:1017–23. 10.1016/j.jacc.2010.02.072
    1. Collection of race and ethnicity data in clinical trials guidance for industry and food and drug administration staff. Available: [Accessed 23 Jan 2018].
    1. Teare MD, Dimairo M, Shephard N, et al. . Sample size requirements to estimate key design parameters from external pilot randomised controlled trials: a simulation study. Trials 2014;15 10.1186/1745-6215-15-264
    1. Kappetein AP, Dawkins KD, Mohr FW, et al. . Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. Eur J Cardiothorac Surg 2006;29:486–91. 10.1016/j.ejcts.2006.01.047
    1. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. . ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/ASE Committee to update the 1997 guidelines for the clinical application of echocardiography). Circulation 2003;108:1146–62. 10.1161/01.CIR.0000073597.57414.A9
    1. Viechtbauer W, Smits L, Kotz D, et al. . A Simple formula for the calculation of sample size in pilot studies. J Clin Epidemiol 2015;68:1375–9. 10.1016/j.jclinepi.2015.04.014
    1. Whitehead AL, Julious SA, Cooper CL, et al. . Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res 2016;25:1057–73. 10.1177/0962280215588241
    1. Cuisset T, Cayla G, Silvain J. Clopidogrel resistance: what's new? Arch Cardiovasc Dis 2010;103:349–53. 10.1016/j.acvd.2010.05.001
    1. Mungrue K, Wyke M, Ramkissoon V, et al. . The distribution of altered forms of CYP2C19*2 allele in a Trinidadian population. is clopidogrel the right choice? Eur J Bio Pharm Sci;3:31–6.
    1. Mega JL, Simon T, Collet JP, et al. . Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304:1821–30. 10.1001/jama.2010.1543
    1. Uchiyama S. Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment. Cardiovasc Ther 2011;29:e100–11. 10.1111/j.1755-5922.2010.00202.x
    1. Subraja K, Dkhar SA, Priyadharsini R, et al. . Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Eur J Clin Pharmacol 2013;69:415–22. 10.1007/s00228-012-1381-8
    1. Chan MY. Clopidogrel pharmacogenetics of East, South and other Asian populations. Eur Heart J Supp 2012;14(suppl A):A41–A42. 10.1093/eurheartj/sur035
    1. Jose R, Chandrasekaran A, Sam SS, et al. . CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the South Indian population. Fundam Clin Pharmacol 2005;19:101–5. 10.1111/j.1472-8206.2004.00307.x
    1. Adithan C, Gerard N, Vasu S, et al. . Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol 2003;56:331–3. 10.1046/j.1365-2125.2003.01883.x
    1. Levine GN, Jeong YH, Goto S, et al. . World heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Glob Heart 2014;9:457–67. 10.1016/j.gheart.2014.08.001
    1. Jeong Y-H. “East asian paradox”: challenge for the current antiplatelet strategy of “one-guideline-fits-all races” in acute coronary syndrome. Curr Cardiol Rep 2014;16 10.1007/s11886-014-0485-4
    1. Kim IS, Choi BR, Jeong YH, et al. . The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. J Thromb Haemost 2009;7:897–9. 10.1111/j.1538-7836.2009.03319.x
    1. Sorich MJ, Rowland A, McKinnon RA, et al. . CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis. Circ Cardiovasc Genet 2014;7:895–902. 10.1161/CIRCGENETICS.114.000669
    1. The World Health Organization Facts and figures about diabetes: country and regional data, 2014. Available:
    1. Yisahak SF, Beagley J, Hambleton IR, et al. . Diabetes in North America and the Caribbean: an update. Diabetes Res Clin Pract 2014;103:223–30. 10.1016/j.diabres.2013.11.009
    1. Mega JL, Braunwald E, Wiviott SD, et al. . Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366:9–19. 10.1056/NEJMoa1112277
    1. Ohman EM, Roe MT, Steg PG, et al. . Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. The Lancet 2017;389:1799–808. 10.1016/S0140-6736(17)30751-1
    1. Gibson CM, Mehran R, Bode C, et al. . Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423–34. 10.1056/NEJMoa1611594
    1. Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract 2004;10:307–12. 10.1111/j.2002.384.doc.x
    1. Arméro S, Camoin Jau L, Omar Aït Mokhtar O, et al. . Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 2010;21:503–7. 10.3109/09537104.2010.499483
    1. Bidet A, Jais C, Puymirat E, et al. . VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation. Platelets 2010;21:94–100. 10.3109/09537100903437206
    1. Peace AJ, Egan K, Kavanagh GF, et al. . Reducing intra-individual variation in platelet aggregation: implications for platelet function testing. J Thromb Haemost 2009;7:1941–3. 10.1111/j.1538-7836.2009.03593.x
    1. Ahn SG, Lee SH, Sung JK, et al. . Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention. Platelets 2011;22:305–7. 10.3109/09537104.2010.525268
    1. Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions: hype or hope? J Am Coll Cardiol 2006;48:1751–4. 10.1016/j.jacc.2006.08.009
    1. Rohla M, Weiss TW, Wojta J, et al. . Double or triple antithrombotic combination therapy in patients who need anticoagulation and antiplatelet therapy in parallel. Eur Heart J Cardiovasc Pharmacother 2015;1:191–7. 10.1093/ehjcvp/pvv014

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel